Novartis generics arm says may sell or end some products

Health Care FOXBusiness

FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann (Reuters)

ZURICH (Reuters) - Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday.

Continue Reading Below

"In response to high price pressure, we are optimizing our U.S. portfolio. This includes the sale or discontinuation of certain non-core products and concentration of investment in strategic areas that will drive growth and improve access," it said in a statement in response to a report by the Swiss newspaper Handelszeitung.

"As we continue to refine our portfolio, it is clear that the U.S. market is a very important market for Sandoz and will continue to be in the future," it added.

More from FOX Business

Reuters had reported last month that Novartis was working with Centerview to examine options for its dermatology business, including a possible sale, as it trims non-core assets. [nL8N1N889J]

(Reporting by Paul Arnold, Editing by Michael Shields)

What do you think?

Click the button below to comment on this article.